VCYT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 6.02%, SMA50 -3.47%, SMA200 13.22%). The stock’s 14-day RSI is 54.98 (neutral), while the ATR of 1.7 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.59% below its high and over 71.38% above its low. Average 10-day trading volume of 1.99 million shares is slightly above the 3-month average of 1.35 million, indicating heightened recent market interest.

Veracyte, Inc. has 78.67 million shares outstanding. The public float is 78.21 million shares, elevated short interest at 11.40% of float. This equals 8.04 million shares. The short ratio is 5.71 days. Institutional investors hold 114.08% of the float. Insiders own 0.54%. Stapley Marc holds 440.49 thousand shares, Chambers Rebecca has 173.28 thousand shares and McGuire Annie has 137.24 thousand shares. Over the past six months, insider transactions show net selling. They sold 255.96 thousand shares across 13 transactions.

Veracyte, Inc. (NASDAQ:VCYT) closed at $46.41 USD, gaining $1.56 (3.48%) from the previous close of $44.85. The stock is currently mid-range between its 52-week high and low $23.79 and $60.91. With a market capitalization of about $3.70 billion, Veracyte, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.93). Key stats such as the average daily volume over the past year has been around 1.36 million shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Veracyte, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Marc Stapley, the company employs approximately 755 people and listed since October 29, 2013. Veracyte, Inc. operates as a diagnostics company in the United States and internationally.

Veracyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $40.98. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 4.03% annually over the next five years. The latest quarter delivered EPS of $0.54. The next quarter is forecast at $0.34. Next year's EPS is expected at $62.14. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 15 Buy ratings, 6 Hold ratings, 0 Sell rating and 5 Strong Sell ratings. Price targets range from $69.00 to $40.00. The high target offers 48.67% upside. The low target suggests -13.81% downside. The mean target is $50.17. This offers 8.1% upside. Veracyte, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended July 30, 2026, missed forecasts by 26.2%. The prior quarter beat by 52.94%. Over the last six quarters, Apple has recorded several small beats. These include 55.0% in May 07, 2025.

Veracyte, Inc. trades at a P/E ratio of 32.09, slightly below the S&P 500 average, with a price-to-sales ratio of 6.56 and a price-to-book ratio of 2.65 suggesting the stock is closer to book value. The P/FCF stands at 22.29, also above market averages.

Veracyte, Inc. (NASDAQ:VCYT) shares are flat -0.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Veracyte, Inc. trading at a premium to the broader market with a P/E of 32.09. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $43.44, suggesting -6.4% downside. Our AI forecast model points to short-term weakness (-3.86% over two weeks), a medium-term rise (84.81% over three months), and a longer-term gain (13.88% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Veracyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.86%, with price expected at $44.62 by August 18, 2026, within a range of $41.53 to $47.49 3-Month Outlook: Projected rise of 84.81%, reaching $85.77 by October 30, 2026, with a range of $84.81 to $87.05. 1-Year Outlook: Projected gain of 13.88%, with price at $52.85 by August 04, 2027, within a range of $50.58 to $55.45.